{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-034294","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2022-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.476699+00:00","generated_at":"2026-06-23T08:18:22.265517+00:00","sec_items":["1.02","5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Roivant terminates $250M Cantor purchase agreement, appoints new director","bullets":["Terminated $250M Common Shares Purchase Agreement with Cantor effective by Oct 5, 2022; entered new Sales Agreement with Cowen on Sept 19, 2022.","Director Masayo Tada resigned effective Sept 16, 2022; no dispute with company or board.","Board appointed Hiroshi Nomura (President/CEO of Sumitomo Pharma) as Class III director effective Sept 16, 2022; waived compensation.","At Sept 15 AGM, shareholders elected Class I directors Gline, Manchester, Epperly and ratified Ernst & Young as auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-034294","json":"https://secwatch.observer/filing/0001140361-22-034294.json","markdown":"https://secwatch.observer/filing/0001140361-22-034294.md","text":"https://secwatch.observer/filing/0001140361-22-034294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/ny20005291x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T08:18:22.265517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"524e06abaa","claim":"Hiroshi Nomura was appointed as Class III director at Roivant Sciences Ltd..","evidence_excerpt":"Also on September 15, 2022, the Board appointed Hiroshi Nomura to serve as a Class III director of the Board, effective September 16, 2022, filling the vacancy created by and concurrent with the resignation of Mr. Tada from the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"aaf608c081","claim":"Masayo Tada resigned as director at Roivant Sciences Ltd..","evidence_excerpt":"On September 15, 2022, Masayo Tada resigned as a director of the Company, effective September 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1635088/000114036122034294/0001140361-22-034294-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}